TAC (Treatment Africa Hepatitis C) : Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TAC
- 10 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2017 Status changed from recruiting to active, no longer recruiting.